NF-kB Signaling Pathway in Neurodegeneration

NF-κB Signaling Pathway in Neurodegeneration

Introduction

The NF-κB (Nuclear Factor Kappa B) signaling pathway stands as one of the most critical and evolutionarily conserved mechanisms for controlling gene expression in response to cellular stress, inflammation, and pathological insults [1](https://pubmed.ncbi.nlm.nih.gov/17072321/). Originally discovered as a transcription factor binding to the immunoglobulin kappa light chain enhancer in B cells, NF-κB has emerged as a central player in neuronal survival, synaptic plasticity, and neuroinflammation - processes fundamental to neurodegenerative disease pathogenesis [2](https://pubmed.ncbi.nlm.nih.gov/16765948/). [@morgan2011]

The NF-κB family comprises five related transcription factors: p50 (NF-κB1), p52 (NF-κB2), RelA (p65), RelB, and c-Rel, which can form homodimers and heterodimers with distinct transcriptional properties and biological functions [3](https://pubmed.ncbi.nlm.nih.gov/17072321/). In the central nervous system, NF-κB is activated in neurons, astrocytes, and microglia in response to various pathological stimuli, with outcomes ranging from neuroprotective gene expression to chronic neuroinflammation and neurodegeneration. [@hamanoue2006]

Pathway Visualization

```mermaid
flowchart TD
A["TNF-alpha<br/>IL-1beta<br/>TLR Ligands"] --> B["Cell Surface<br/>Receptors"]

B --> C["Adaptor Proteins<br/>MyD88, TRIF"]

C --> D["IKK Complex<br/>(IKKalpha, IKKbeta, IKKgamma)"]

D -->|"Phosphorylation"| E["IkappaBalpha<br/>Degradation"]

E -->|"Release"| F["NF-kappaB<br/>(p50/p65)"]

NF-κB Signaling Pathway in Neurodegeneration

Introduction

The NF-κB (Nuclear Factor Kappa B) signaling pathway stands as one of the most critical and evolutionarily conserved mechanisms for controlling gene expression in response to cellular stress, inflammation, and pathological insults [1](https://pubmed.ncbi.nlm.nih.gov/17072321/). Originally discovered as a transcription factor binding to the immunoglobulin kappa light chain enhancer in B cells, NF-κB has emerged as a central player in neuronal survival, synaptic plasticity, and neuroinflammation - processes fundamental to neurodegenerative disease pathogenesis [2](https://pubmed.ncbi.nlm.nih.gov/16765948/). [@morgan2011]

The NF-κB family comprises five related transcription factors: p50 (NF-κB1), p52 (NF-κB2), RelA (p65), RelB, and c-Rel, which can form homodimers and heterodimers with distinct transcriptional properties and biological functions [3](https://pubmed.ncbi.nlm.nih.gov/17072321/). In the central nervous system, NF-κB is activated in neurons, astrocytes, and microglia in response to various pathological stimuli, with outcomes ranging from neuroprotective gene expression to chronic neuroinflammation and neurodegeneration. [@hamanoue2006]

Pathway Visualization

NF-κB Signaling Mechanisms

Canonical Pathway

The classical or canonical NF-κB activation pathway is triggered by pro-inflammatory cytokines, pathogen-associated molecular patterns (PAMPs), and damage-associated molecular patterns (DAMPs): [@heneka2015]

Receptor activation: [@craft2005]

• TNF-α, IL-1β, and TLR ligands activate their respective receptors
• Leads to recruitment of adaptor proteins (MyD88, TRIF, TRADD)
• Activation of upstream kinases [4](https://pubmed.ncbi.nlm.nih.gov/16765948/)

• IKKα, IKKβ, and IKKγ (NEMO) form the IKK complex
• IKKβ mediates canonical pathway activation
• Phosphorylates IκBα on Ser32 and Ser36 [5](https://pubmed.ncbi.nlm.nih.gov/17072321/)

• Phosphorylated IκBα undergoes ubiquitination
• Degraded by the 26S proteasome
• Releases p50/RelA dimers to translocate to nucleus [6](https://pubmed.ncbi.nlm.nih.gov/17072321/)

• NF-κB dimers bind to κB sites in DNA
• Recruit coactivators (p300/CBP)
• Activate inflammatory and survival genes [7](https://pubmed.ncbi.nlm.nih.gov/16765948/)

Non-Canonical Pathway

The alternative NF-κB pathway responds to specific stimuli: [@zhang2015]

NF-κB-inducing kinase (NIK): [@aggarwal2007]

• Activated by lymphotoxin-β, CD40, BAFF
• Phosphorylates and activates IKKα
• Processes p100 to p52 [8](https://pubmed.ncbi.nlm.nih.gov/17072321/)

• p52/RelB dimers translocate to nucleus
• Regulates distinct gene sets
• Important for B cell function and lymphoid organogenesis [9](https://pubmed.ncbi.nlm.nih.gov/17072321/)

Atypical Pathways

NF-κB can be activated independently of IKK: [@fellner2013]

DNA damage: [@tansey2010]

• ATM and ATR kinases can activate NF-κB
• Response to genotoxic stress
• Cell survival decisions [10](https://pubmed.ncbi.nlm.nih.gov/17072321/)

• Direct modification of IKK
• Redox-sensitive activation
• Links metabolism to inflammation [11](https://pubmed.ncbi.nlm.nih.gov/16765948/)

• Trk receptors can activate NF-κB
• Cross-talk with survival pathways
• Neuronal protection [12](https://pubmed.ncbi.nlm.nih.gov/16765948/)

NF-κB in Alzheimer's Disease

Amyloid-β-Induced Neuroinflammation

Aβ activates NF-κB in multiple cell types: [@glass2010]

Microglial activation: [@clement2003]

• Aβ oligomers and fibrils activate TLR4 and RAGE
• Triggers robust NF-κB activation
• Pro-inflammatory cytokine production [13](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Aβ stimulates astrocyte NF-κB
• Glial fibrillary acidic protein (GFAP) expression
• Chronic neuroinflammation [14](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Aβ can activate neuronal NF-κB
• Both protective and detrimental effects
• Context-dependent outcomes [15](https://pubmed.ncbi.nlm.nih.gov/25448317/)

Tau Pathology and NF-κB

Tau pathology intersects with NF-κB signaling: [@ilieva2009]

Kinase pathways: [@tsvetkov2010]

• GSK-3β and CDK5 link tau phosphorylation to NF-κB
• Bidirectional activation
• Amplifies pathology [16](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Tau mislocalization activates NF-κB
• Synaptic deficits
• Cognitive decline [17](https://pubmed.ncbi.nlm.nih.gov/25448317/)

Therapeutic Targeting

Modulating NF-κB in AD: [@gordon2010]

IKK inhibitors: [@colton2006]

• BAY 11-7082 and derivatives
• Neuroprotective in models
• Clinical translation challenges [18](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Curcumin, resveratrol, EGCG
• NF-κB modulatory activity
• Epidemiologic evidence [19](https://pubmed.ncbi.nlm.nih.gov/25448317/)

NF-κB in Parkinson's Disease

Dopaminergic Neurodegeneration

NF-κB mediates dopaminergic neuron death: [@murray2011]

Microglial activation: [@meberg2000]

• Activated microglia surround Lewy bodies
• NF-κB-driven cytokine production
• Chronic neuroinflammation [20](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Pathological α-Synuclein activates NF-κB
• TLR4-mediated recognition
• Spreads pathology [21](https://pubmed.ncbi.nlm.nih.gov/25448317/)

Neuroinflammation

Inflammatory mechanisms in PD: [@sheng1990]

Cytokine profile: [@steward2001]

• Elevated TNF-α, IL-1β, IL-6 in PD brain
• CSF and blood markers
• Correlates with progression [22](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• M1 (pro-inflammatory) vs. M2 (protective)
• NF-κB drives M1 polarization
• Therapeutic modulation potential [23](https://pubmed.ncbi.nlm.nih.gov/25448317/)

Therapeutic Implications

Targeting NF-κB in PD: [@mattson2005]

Anti-inflammatory strategies: [@rando2008]

• Minocycline and derivatives
• NSAID use and PD risk
• Clinical trial results [24](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• IKKβ inhibitors
• microRNA-based therapy
• Cell-type specificity [25](https://pubmed.ncbi.nlm.nih.gov/25448317/)

NF-κB in Amyotrophic Lateral Sclerosis

Motor Neuron Degeneration

NF-κB contributes to ALS pathogenesis: [@watanabe2013]

SOD1 mutations: [@podar2008]

• Mutant SOD1 triggers NF-κB
• Astrocyte and microglia activation
• Non-cell autonomous degeneration [26](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• TDP-43 aggregates activate NF-κB
• Ubiquitination stress
• RNA metabolism links [27](https://pubmed.ncbi.nlm.nih.gov/25448317/)

Glial Activation

Neuroinflammation in ALS: [@raghav2012]

Astrocyte reactivity: [@goel2010]

• Pro-inflammatory phenotype
• NF-κB-dependent toxicity
• Motor neuron vulnerability [28](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Chronic activation
• Mutant SOD1 effects
• Disease progression correlation [29](https://pubmed.ncbi.nlm.nih.gov/25448317/)

NF-κB in Huntington's Disease

Mutant Huntingtin Effects

NF-κB dysregulation in HD: [@elmore2014]

Transcriptional alterations: [@london2013]

• Mutant huntingtin affects NF-κB localization
• Altered gene expression
• Neuronal dysfunction [30](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Elevated NF-κB activity
• Glial activation
• Contributes to degeneration [31](https://pubmed.ncbi.nlm.nih.gov/25448317/)

NF-κB in Neuroinflammation

Microglial Polarization

NF-κB defines microglial phenotypes: [@cagnin2015]

M1 polarization: [@bhakar2003]

• Classical activation by IFN-γ and LPS
• NF-κB drives pro-inflammatory state
• Neurotoxic effects [32](https://pubmed.ncbi.nlm.nih.gov/16765948/)

• Alternative activation by IL-4, IL-13
• Anti-inflammatory phenotype
• Neuroprotective functions [33](https://pubmed.ncbi.nlm.nih.gov/16765948/)

Cytokine Network

NF-κB-regulated cytokines: [@damelio2011]

Pro-inflammatory: [@chiou2013]

• TNF-α, IL-1β, IL-6, IL-8
• Chemokines (CCL2, CXCL10)
• Matrix metalloproteinases [34](https://pubmed.ncbi.nlm.nih.gov/16765948/)

• IL-10, TGF-β
• Negative feedback loops
• Resolution mechanisms [35](https://pubmed.ncbi.nlm.nih.gov/16765948/)

NF-κB in Synaptic Plasticity

Learning and Memory

NF-κB regulates synaptic plasticity: [@collins1995]

LTP and LTD: [@gaffen2009]

• NF-κB required for LTP
• Activity-dependent activation
• Memory consolidation [36](https://pubmed.ncbi.nlm.nih.gov/16765948/)

• Homeostatic plasticity
• NF-κB mediates scaling responses
• Circuit stability [37](https://pubmed.ncbi.nlm.nih.gov/16765948/)

Gene Expression

Activity-dependent transcription: [@lee2011]

Immediate early genes: [@vargas2013]

• c-Fos, c-Jun regulation
• Synaptic activity responses
• Plasticity-related genes [38](https://pubmed.ncbi.nlm.nih.gov/16765948/)

• NMDA and AMPA receptor subunits
• Scaffolding proteins
• Vesicle proteins [39](https://pubmed.ncbi.nlm.nih.gov/16765948/)

NF-κB in Neuronal Survival

Pro-Survival Functions

NF-κB can be neuroprotective: [@kinoshita2012]

Anti-apoptotic genes: [@dirnagl1999]

• Bcl-2, Bcl-xL expression
• Inhibitor of apoptosis proteins (IAPs)
• Antioxidant enzymes [40](https://pubmed.ncbi.nlm.nih.gov/16765948/)

• NGF and BDNF regulation
• Cross-talk with Trk receptors
• Neuronal maintenance [41](https://pubmed.ncbi.nlm.nih.gov/16765948/)

Context-Dependent Effects

The nature of NF-κB activation determines outcome: [@wellen2009]

Stimulus matters: [@shimada2012]

• Acute vs. chronic activation
• Intensity and duration
• Cell type specificity [42](https://pubmed.ncbi.nlm.nih.gov/16765948/)

• p50/RelA vs. p50/p50 dimers
• Transcriptional specificity
• Gene-specific effects [43](https://pubmed.ncbi.nlm.nih.gov/16765948/)

Therapeutic Strategies

IKK Inhibitors

Targeting the IKK complex: [@liu2013]

BAY 11-7082: [@tabas2010]

• IKKβ inhibition
• Reduces neuroinflammation
• Preclinical efficacy [44](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Selective IKKβ inhibitor
• Clinical trials in autoimmune disease
• Potential for neurodegeneration [45](https://pubmed.ncbi.nlm.nih.gov/25448317/)

NF-κB DNA Binding Inhibitors

Preventing NF-κB DNA interaction: [@djavaherimergny2010]

Proteasome inhibitors: [@moscat2011]

• Bortezomib effects
• IκB stabilization
• CNS penetration challenges [46](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Gene therapy approach
• Preclinical studies
• Delivery challenges [47](https://pubmed.ncbi.nlm.nih.gov/25448317/)

Natural Products

Dietary and plant-derived compounds: [@kang2013]

Curcumin: [@pacher2007]

• IKK inhibition
• Multiple targets
• Bioavailability issues [48](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• SIRT1 activation
• NF-κB modulation
• Clinical trials ongoing [49](https://pubmed.ncbi.nlm.nih.gov/25448317/)

Targeted Approaches

Cell-type specific modulation: [@franceschi2007]

Microglial targeting: [@salminen2011]

• CSF1R inhibitors
• Colony-stimulating factor 1
• Reduces microglial proliferation [50](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Viral vector delivery
• Dominant-negative constructs
• Gene therapy [51](https://pubmed.ncbi.nlm.nih.gov/25448317/)

Biomarkers

NF-κB Activity Markers

Measuring NF-κB activation: [@oh2014]

Transcriptional markers: [@scheiermann2012]

• NF-κB target gene expression
• Cytokine levels
• Peripheral blood mononuclear cells [52](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• TSPO PET for neuroinflammation
• Correlates with NF-κB
• Disease progression tracking [53](https://pubmed.ncbi.nlm.nih.gov/25448317/)

Research Models

Cellular Models

Studying NF-κB in vitro: [@zhang2012a]

Primary neuron cultures: [@kumar2015]

• Lentiviral approaches
• Primary glia cultures
• Co-culture systems [54](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• Patient-specific models
• Disease mechanism studies
• Drug screening [55](https://pubmed.ncbi.nlm.nih.gov/25448317/)

Animal Models

In vivo studies: [@loane2012]

Transgenic mice: [@beton2012]

• NF-κB reporter lines
• Conditional knockouts
• Disease model crosses [56](https://pubmed.ncbi.nlm.nih.gov/25448317/)

• AAV-mediated expression
• Stereotaxic injection
• Region-specific manipulation [57](https://pubmed.ncbi.nlm.nih.gov/25448317/)

NF-κB in Multiple Sclerosis

Demyelination and Axonal Injury

NF-κB plays a complex role in MS pathogenesis. In oligodendrocyte precursors, NF-κB activation regulates myelin gene expression and influences demyelination processes [58](https://pubmed.ncbi.nlm.nih.gov/18414406/). The blood-brain barrier disruption seen in MS involves NF-κB-regulated adhesion molecules including VCAM-1 and ICAM-1, which facilitate leukocyte infiltration into the central nervous system [59](https://pubmed.ncbi.nlm.nih.gov/16039992/). Autoimmune mechanisms in MS involve both Th1 and Th17 responses, with NF-κB controlling IFN-γ and IL-17 signaling that drives autoimmune progression [60](https://pubmed.ncbi.nlm.nih.gov/19575679/). B cell involvement in MS includes antibody production with NF-κB playing essential roles in plasma cell survival and myelin target recognition [61](https://pubmed.ncbi.nlm.nih.gov/22797636/). [@beattie2002]

NF-κB in Prion Diseases

Cellular prion protein (PrP^Sc) aggregation activates NF-κB, triggering neuronal stress responses that contribute to neurodegeneration progression [62](https://pubmed.ncbi.nlm.nih.gov/21763213/). Chronic microglial activation in prion disease correlates with cytokine production and disease timeline [63](https://pubmed.ncbi.nlm.nih.gov/23707148/).

NF-κB in Frontotemporal Dementia

FTD tauopathy involves MAPT mutations that link tau pathology to NF-κB activation, resulting in neuronal dysfunction and behavioral variant presentations [64](https://pubmed.ncbi.nlm.nih.gov/21958453/). Progranulin deficiency in FTD leads to lysosomal dysfunction and NF-κB dysregulation, contributing to ubiquitin pathology [65](https://pubmed.ncbi.nlm.nih.gov/22810101/). [@choi2014]

NF-κB in Vascular Dementia

Ischemic injury from stroke triggers immediate NF-κB activation, initiating inflammatory cascades and blood-brain barrier breakdown [66](https://pubmed.ncbi.nlm.nih.gov/10441335/). Chronic hypoperfusion leads to white matter lesions mediated by NF-κB, contributing to cognitive decline in vascular dementia [67](https://pubmed.ncbi.nlm.nih.gov/9876458/). [@vezzani2013]

NF-κB and Mitochondrial Dysfunction

Energy Metabolism Cross-talk

NF-κB interacts with PGC-1α to regulate mitochondrial biogenesis, enabling metabolic adaptation in neurons [68](https://pubmed.ncbi.nlm.nih.gov/19147869/). Mitochondrial DNA release activates the NLRP3 inflammasome through cytosolic DNA sensing, contributing to chronic neuroinflammation [69](https://pubmed.ncbi.nlm.nih.gov/22306005/). [@rana2012]

Mitophagy and Protein Quality Control

The PINK1/Parkin pathway for mitophagy is regulated by NF-κB, supporting protein quality control and neuronal survival [70](https://pubmed.ncbi.nlm.nih.gov/22461784/). Dysfunctional mitophagy leads to accumulation of damaged mitochondria, increased ROS production, and neurodegeneration [71](https://pubmed.ncbi.nlm.nih.gov/23954642/). NF-κB also regulates autophagy through Beclin-1 and p62/SQSTM1, with context-dependent pro-survival or pro-death outcomes [74](https://pubmed.ncbi.nlm.nih.gov/20168081/)[75](https://pubmed.ncbi.nlm.nih.gov/21934778/). [@barkerhaliski2014]

NF-κB and Oxidative Stress

Reactive oxygen species directly modify IKK through thiol oxidation, providing redox-sensitive NF-κB activation that links metabolism to inflammation [76](https://pubmed.ncbi.nlm.nih.gov/16517406/). NF-κB cross-talks with Nrf2 to induce antioxidant responses including HO-1 expression, providing neuroprotection [77](https://pubmed.ncbi.nlm.nih.gov/23569277/). Nitric oxide signaling induces iNOS expression through NF-κB-dependent mechanisms, though S-nitrosylation of IKK provides negative feedback [78](https://pubmed.ncbi.nlm.nih.gov/17638845/)[79](https://pubmed.ncbi.nlm.nih.gov/10744284/). [@jin2009]

NF-κB in Aging and Brain Aging

The inflammaging concept describes chronic low-grade NF-κB activation during brain aging, contributing to cognitive decline [80](https://pubmed.ncbi.nlm.nih.gov/17619994/). Age-related decline in SIRT1 affects NF-κB regulation, with therapeutic implications for age-related neurological conditions [81](https://pubmed.ncbi.nlm.nih.gov/21537423/). Cellular senescence involves NF-κB-driven senescence-associated secretory phenotype (SASP), which promotes chronic inflammation and paracrine effects that impair the neural stem cell niche [82](https://pubmed.ncbi.nlm.nih.gov/20357733/)[83](https://pubmed.ncbi.nlm.nih.gov/25446849/). [@tsuda2011]

NF-κB and Circadian Rhythm

BMAL1/CLOCK clock genes interact with NF-κB in transcriptional cross-talk, creating time-of-day effects on immune regulation [84](https://pubmed.ncbi.nlm.nih.gov/22325227/). Sleep disruption activates NF-κB with inflammatory consequences that may increase neurodegeneration risk [85](https://pubmed.ncbi.nlm.nih.gov/23155152/). [@kelleher2013]

NF-κB in Traumatic Brain Injury

Acute TBI triggers immediate NF-κB activation, initiating inflammatory cascades that cause blood-brain barrier disruption and secondary damage [86](https://pubmed.ncbi.nlm.nih.gov/22450242/). Chronic phase TBI involves long-term inflammation leading to neurodegeneration and cognitive deficits [87](https://pubmed.ncbi.nlm.nih.gov/26246902/). IKK inhibitors show neuroprotective effects in acute TBI, though timing considerations are critical [88](https://pubmed.ncbi.nlm.nih.gov/21658955/). Anti-inflammatory strategies combined with rehabilitation may improve chronic TBI outcomes [89](https://pubmed.ncbi.nlm.nih.gov/22192327/). [@peterson2014]

NF-κB in Spinal Cord Injury

SCI triggers an immediate NF-κB inflammatory cascade causing secondary damage and neutrophil infiltration [90](https://pubmed.ncbi.nlm.nih.gov/22875583/). Apoptotic pathways activated by NF-κB contribute to neuronal death, axonal degeneration, and functional impairment [91](https://pubmed.ncbi.nlm.nih.gov/12445562/). Anti-inflammatory treatment during the acute phase provides neuroprotection through timing-optimized intervention [92](https://pubmed.ncbi.nlm.nih.gov/12124626/). NF-κB modulation can promote regeneration through growth factor expression and neural stem cell activation [93](https://pubmed.ncbi.nlm.nih.gov/22735306/). [@liu2013a]

NF-κB in Epilepsy

Acute seizures trigger rapid NF-κB activation leading to cytokine induction and neuronal hyperexcitability [94](https://pubmed.ncbi.nlm.nih.gov/24126265/). Chronic epilepsy involves recurrent NF-κB activation, blood-brain barrier dysfunction, and neurodegeneration [95](https://pubmed.ncbi.nlm.nih.gov/23993641/). Some antiepileptic drugs have NF-κB modulatory effects with anti-inflammatory properties that may provide disease modification [96](https://pubmed.ncbi.nlm.nih.gov/22811384/). Novel strategies including IKK inhibitors and microRNA targeting offer potential for gene therapy approaches [97](https://pubmed.ncbi.nlm.nih.gov/25009501/). [@tezel2010]

NF-κB in Chronic Pain

Peripheral sensitization in DRG neurons involves NF-κB activation leading to cytokine production and hyperalgesia development [98](https://pubmed.ncbi.nlm.nih.gov/19394251/). Central sensitization in the spinal cord involves NF-κB-driven glial activation that maintains chronic pain states [99](https://pubmed.ncbi.nlm.nih.gov/22037309/). Local peripheral NF-κB inhibition provides analgesic effects with reduced side effects [100](https://pubmed.ncbi.nlm.nih.gov/23685058/). Spinal delivery of NF-κB inhibitors offers opioid-sparing effects for chronic pain management [101](https://pubmed.ncbi.nlm.nih.gov/24906965/).

NF-κB in Retinal Degeneration

In age-related macular degeneration, NF-κB in retinal pigment epithelial cells contributes to choroidal neovascularization and photoreceptor loss [102](https://pubmed.ncbi.nlm.nih.gov/24041615/). Glaucoma involves NF-κB-mediated Müller cell activation contributing to optic nerve degeneration and retinal ganglion cell death [103](https://pubmed.ncbi.nlm.nih.gov/20505669/).

Cross-Links and Further Reading

Related Signaling Pathways

• [MAPK Signaling Pathway](/mechanisms/mapk-signaling-neurodegeneration) - MAP kinases interact with NF-κB in stress responses
• [JAK-STAT Signaling](/mechanisms/jak-stat-signaling-pathway) - Cytokine signaling cross-talk with NF-κB
• [PI3K-AKT Pathway](/mechanisms/pi3k-akt-signaling-pathway) - Pro-survival signaling intersects with NF-κB
• [WNT Signaling](/mechanisms/wnt-signaling-pathway) - Developmental pathways in neurodegeneration

Related Proteins and Genes

• [TNF](/proteins/tnf-alpha-protein) - Major NF-κB activator
• [IL1B](/proteins/il1b-protein) - Pro-inflammatory cytokine
• [IKBKB](/genes/ikbkb) - IKKβ catalytic subunit
• [RELA](/genes/rela) - RelA/p65 transcription factor

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)

Related Cell Types

• [Microglia](/cell-types/microglia)
• [Astrocytes](/cell-types/astrocytes)
• [Oligodendrocytes](/cell-types/oligodendrocytes)
• [Neurons](/cell-types/neurons)

Conclusion

The NF-κB signaling pathway occupies a central position in neurodegenerative disease pathogenesis, mediating the complex interplay between neuroinflammation, neuronal survival, and synaptic plasticity. While NF-κB activation can be neuroprotective through induction of anti-apoptotic and antioxidant genes, chronic or dysregulated activation drives progressive neuroinflammation that contributes to neuronal dysfunction and death. The context-dependent nature of NF-κB signaling, determined by the stimulus, cell type, and dimer composition, presents both challenges and opportunities for therapeutic intervention. Developing strategies that selectively modulate NF-κB activity to promote neuroprotection while suppressing neuroinflammation remains an important goal for neurodegenerative disease treatment.

See Also

• [MAPK Signaling Pathway](/mechanisms/mapk-signaling-neurodegeneration)
• [JAK-STAT Signaling](/mechanisms/jak-stat-signaling-pathway)
• [PI3K-AKT Pathway](/mechanisms/pi3k-akt-signaling-pathway)
• [WNT Signaling](/mechanisms/wnt-signaling-pathway)
• [TNF](/proteins/tnf-alpha-protein)
• [IL1B](/proteins/il1b-protein)
• [IKBKB](/genes/ikbkb)
• [RELA](/genes/rela)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References